You are here

  • Home
  • Archive
  • Volume 72, Issue 1
  • Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial

Citation Tools

Article menu
Download PDFPDF
Letters
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Pollard RPE, Abdulahad WH, Vissink A, et al
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial
Annals of the Rheumatic Diseases 2013;72:146-148.